Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors

NCT06853080 is registered in ClinicalTrials.gov with Taipei Medical University as lead sponsor.

NCT NCT06853080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06853080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors
Lead sponsor
Taipei Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 2, 2020
Completion date
December 31, 2025
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumors (at/rts), central nervous system (cns) tumors